A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases

The development of broad-spectrum antivirals against human coronaviruses (HCoVs) is critical to combat the current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, as well as future outbreaks of emerging CoVs. We ha...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jie Zhou, Wei Xu, Zezhong Liu, Chao Wang, Shuai Xia, Qiaoshuai Lan, Yanxing Cai, Shan Su, Jing Pu, Lixiao Xing, Youhua Xie, Lu Lu, Shibo Jiang, Qian Wang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2022-04-01
Series:	Acta Pharmaceutica Sinica B
Assuntos:	Coronavirus Lipopeptide SARS-CoV-2 Polyethylene glycol Fusion inhibitor
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2211383521002756
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!